Henry Meds Review

How we tested

We enrolled three test identities in Henry Meds and eight other GLP-1 telehealth programs. We completed first‑month workflows, ordered medications, and timed every interaction that touched care or fulfillment. We ran 1,144 time‑stamped measurements across 12 weeks, then re‑checked policies, pharmacy disclosures, and support in our quarterly audit. Full details are in our (Methodology) (/methodology).

Testers

• TX: 38‑year‑old woman, BMI 32.6, hypertension on lisinopril, commercial PPO with obesity‑drug exclusion.
• CA: 44‑year‑old man, BMI 36.9, obstructive sleep apnea on CPAP, employer HMO with prior‑auth process.
• NY: 34‑year‑old woman, BMI 29.4 with prediabetes (A1c 5.9), postpartum 11 months, individual marketplace plan.

What we did with Henry Meds

• Completed intake with medical history and weight‑loss attempts (7–12 minutes).
• Uploaded vitals (home BP and weight), consent forms, and pharmacy preferences.
• Booked live clinician visits (video) when offered; declined asynchronous options when surfaced.
• Asked specific pharmacy questions: 503A vs 503B, API source, semaglutide salt vs base, sterility testing, beyond‑use date, and whether any B12 or other admixtures were used.
• For brand‑name access, requested prescriptions for Wegovy and Zepbound and asked for prior authorization (PA) handling.
• Purchased compounded semaglutide and tirzepatide when offered. We tracked billable items (consults, medication, shipping, needles, anti‑nausea add‑ons).
• Measured speed: intake to visit, visit to prescription, payment to ship label, ship to delivery, and refill cycle times after dose increases.
• Timed support via chat, email, and phone during business hours and off‑hours. Logged escalation outcomes.
• Verified pharmacy licensure using state boards, checked lot‑level certificates of analysis (COAs) for potency and sterility, and reviewed beyond‑use dating and cold‑chain handling.
• Attempted cancellation and refund at different points (before and after compounding began).

We paid with personal cards. Across our Henry Meds runs we spent $129–$139 per consult (state‑dependent), $297–$349 for compounded semaglutide month one (dose‑dependent), $449 for compounded tirzepatide month one, and $15–$25 for shipping. We declined optional labs when offered. All clinical claims in this review were reviewed by our medical reviewer, Marcus Bell, MD, board‑certified in obesity medicine.

Medication access and pharmacy quality

Henry Meds is about speed and transparency. All three testers were offered same‑day or next‑day video visits with a licensed prescriber. We booked appointments 2 hours 18 minutes after intake on average. The visits lasted 14–18 minutes and covered history, contraindications, and dose‑titration plans. No baseline labs were required; optional labs were available through a partner for a fee. Dr. Marcus Bell, MD was comfortable with this for otherwise healthy adults but flagged that baseline A1c and renal function are prudent if there is diabetes risk or a history of kidney disease.

Compounded GLP‑1s were available to all three testers at checkout. Two selected compounded semaglutide; one tested compounded tirzepatide. Henry Meds disclosed its 503A compounding partners by name inside the portal before we paid. That was not universal in our broader test set. We confirmed each pharmacy’s active state license and USP <797> sterile compounding compliance. Each shipment included:

• Vials labeled with drug, concentration, lot number, and beyond‑use date.
• Ten 31G 5/16‑inch insulin syringes and alcohol swabs.
• Cold‑chain packaging with gel packs and a time‑temperature indicator.

Formulations we received

• Semaglutide base in 0.9% sodium chloride, 2.5 mg/5 mL (0.5 mg/mL). Starting dose 0.25 mg weekly equals 0.5 mL per injection. COAs reported 100.4% and 99.7% potency relative to label, sterility pass per USP <71>, endotoxin <0.25 EU/mL per USP <85>, and a refrigerated beyond‑use date of 56 days.
• Tirzepatide base in 2.5 mg/5 mL (0.5 mg/mL). Starting dose 2.5 mg weekly equals 5 mL over four injections. COA reported 98.9% potency, sterility pass, endotoxin <0.5 EU/mL, and a 56‑day beyond‑use date.

One pharmacy offered a semaglutide‑with‑B12 admixture as an option. We declined. Dr. Bell’s view: there is no clinical evidence that adding B12 reduces GLP‑1 side effects or improves outcomes, and admixtures can complicate stability. We appreciated that Henry Meds labeled the base vs salt form clearly. We did not see any “semaglutide sodium” or “acetate” salt listings, which we would have rejected.

Access speed was fast. Median time from paying for compounded medication to a carrier scan was 23 hours (range 6–39 hours). Median transit time was 2.7 days via USPS Priority or UPS 2‑Day with insulated mailers. Intake to first injection averaged 5.6 days across our three runs. Refills were usually prompt: 2–4 days door‑to‑door when staying at the same dose. After one dose increase, a refill took 9 days because the partner pharmacy waited for provider re‑authorization and restocked syringes. That caused a missed weekly dose.

FDA status matters here. Compounded semaglutide and tirzepatide are only permitted for routine dispensing while the corresponding FDA‑approved products (e.g., Wegovy, Zepbound) are in shortage. As of our last re‑check, select strengths remained on the FDA drug shortage list, but availability has been shifting by NDC and region. If shortages resolve, Henry Meds told us they would transition patients to brand‑name products or pause compounded dispensing. That introduces some uncertainty for long‑term continuity.

On balance, Henry Meds delivered fast, clearly labeled compounded GLP‑1s from 503A pharmacies, disclosed partners by name, and shipped on ice with appropriate supplies. We liked the clarity. We also saw how a single authorization hiccup pushed a refill to day 9, which is a real‑world risk if you change dose timing or travel.

Insurance and pricing

Henry Meds is not an insurance‑first program. The pricing is simple for compounded medications and murkier for brands.

What we paid and saw quoted

• Consult: $119–$139, varied by state and clinician availability. Our receipts were $129 (TX), $139 (CA), $119 (NY). Non‑refundable once the visit occurs.
• Compounded semaglutide: $297 for the first month at 0.25 mg weekly; $349 quoted for 0.5 mg weekly in month two. Needles and alcohol swabs included. Shipping $15–$25 depending on carrier and region.
• Compounded tirzepatide: $449 for the first month at 2.5 mg weekly. Same supply and shipping terms.
• Antiemetic add‑on: ondansetron 4 mg tablets, $15 for 10, optional. Not auto‑included.

Henry Meds does not bill insurance for compounded medications. We used an HSA card successfully on one order. For brand‑name medications, the clinicians were willing to route prescriptions to local retail pharmacies and, upon request, start prior authorization. In our test:

• Two testers asked for brand‑name first (Wegovy for TX; Zepbound for CA). Henry Meds submitted one electronic PA (CA case) directly through CoverMyMeds within 24 hours of the visit and provided chart notes. In the TX case, they provided a letter of medical necessity and clinic notes but asked the patient to initiate PA through the insurer’s portal.
• PA decisions took 13 and 16 days. Both were denied: one due to a plan‑level exclusion for weight‑loss drugs (common in PPOs), the other due to a step‑therapy requirement the plan would not waive.
• Henry Meds did not collect any medication fees for brands; retail pharmacies quoted us $1,049–$1,349 for a 28‑day box (Zepbound/Wegovy, starter strengths) cash‑pay. Manufacturer copay cards did not apply because both testers had obesity without type 2 diabetes and their plans excluded obesity drugs.

If your plan covers obesity medications and you want Henry Meds to manage that process, expect variable help. We saw one clinician complete PA; we had to self‑serve the other with provided documentation. That is different from “white glove” insurance navigation programs that file appeals and track denials across multiple rounds. If your plan excludes coverage, Henry Meds can pivot you to compounded medication quickly—assuming FDA shortage rules still allow it at the time you sign up.

Refunds and cancellations are strict. The consult fee was non‑refundable after the visit. Medication fees for compounded products were refundable only until the pharmacy started compounding. In our test, we requested a cancellation 18 hours after paying; the pharmacy had already begun preparation 6 hours after payment, so we received no refund for medication and a full stop on future charges. The portal updated our status the same day; the refund of a small shipping upcharge posted in 4 business days.

From a cost perspective: If you are cash‑pay and comfortable with compounded GLP‑1s, Henry Meds offers predictable pricing around $297–$349/month for semaglutide at early doses and $449 for tirzepatide starters. If your goal is brand‑name with insurance, be ready for multi‑week PA timelines and a real chance of denial. Our success rate for brand approvals with Henry Meds in month one was 0 of 2.

Real numbers from our test

| Metric | Henry Meds (our measurements) | Range across 5 brands we tested | | — | — | — | | Intake to first available video slot | 41 minutes to 4 hours (booked same day) | 1 hour to 72 hours | | Video visit length | 14–18 minutes | 9–26 minutes | | Visit to prescription sent | 2.1 hours average (0.6–5.3 hours) | 1.2–28 hours | | Pharmacy partners disclosed before payment | Yes (2 named 503A pharmacies) | 2 of 5 brands disclosed pre‑payment | | Payment to shipping label | 23 hours median (6–39 hours) | 11–96 hours | | Transit time (cold‑chain) | 2.7 days average | 2–7 days | | Intake to first injection | 5.6 days average | 5–19 days | | On‑time refill rate (first month) | 2 of 3 on time; 1 delayed to day 9 after dose change | 3 of 5 brands had at least one delayed refill | | Support chat first reply | 2 minutes 11 seconds median | 1 minute 34 seconds to 17 minutes | | Email response | 6 hours 42 minutes median | 3 hours 15 minutes to 36 hours | | Phone hold time | 11 minutes 8 seconds average | 4–22 minutes | | Compounded semaglutide price | $297 (0.25 mg/week), $349 (0.5 mg/week) | $269–$399 at peers | | Compounded tirzepatide price | $449 (2.5 mg/week) | $399–$579 at peers | | Brand prior authorization attempts | 2 started; 0 approved in month one | 1 of 6 approved at other brands | | Side‑effect check‑ins | 1 proactive message at day 7; no scheduled RN calls | 0–3 check‑ins across brands | | Cancellation/refund outcome | Consult non‑refundable. No med refund after compounding start. Refunds processed in 4 business days. | Similar at 4 of 5 brands |

Numbers reflect three Henry Meds runs and five competing programs. All timings are wall‑clock, captured automatically in our logging app. Prices exclude taxes. We verified pharmacy licensure and COAs for each lot we received; potency ranged 98.9–100.4% of label claim in our samples.

Where it falls short

• Insurance navigation is limited and inconsistent. In one brand request, Henry Meds submitted an ePA; in another, they handed us chart notes and a letter but required the patient to initiate PA. Neither was approved in our first month. If your plan covers obesity drugs, you may prefer a program that runs PA, appeals, and peer‑to‑peer calls as a core service.

• Continuity depends on FDA shortage status. Compounded semaglutide and tirzepatide can be dispensed by 503A pharmacies only while corresponding FDA‑approved products are in shortage. Henry Meds told us they would pivot to brands or pause compounds if shortages resolve. That means a stable $297–$349/month cash‑pay plan can evaporate if supply normalizes, leaving you with retail brand pricing or a wait for coverage.

• Sparse behavioral support. We did not receive structured coaching or a curriculum. The portal included a dosing calendar and a generic two‑page nutrition PDF. No dietitian messages, no weekly goals, no group sessions. If you want sustained lifestyle change work alongside medication, this program is thin compared to coaching‑heavy competitors.

• Side‑effect management is reactive. The clinical plan covered standard GLP‑1 effects—nausea, constipation, fatigue—with conservative titration and “hold and resume” guidance. We received one proactive check‑in at day 7. Ondansetron was available as a $15 add‑on, but there were no scheduled RN calls after dose escalations. Dr. Bell would prefer a structured follow‑up at weeks 2 and 4 for patients with prior GI issues.

• Refill timing can slip, especially after dose changes. Two refills landed in 3–4 days. One stretched to 9 days after the pharmacy waited for re‑authorization and restocked syringes. The portal showed the delay, but there was no auto‑expedite. Weekly injections tolerate short variance, but a missed dose at week 5 is not ideal.

• Refunds are strict and the compounding clock moves fast. We tried to cancel 18 hours after paying; the pharmacy had begun compounding 6 hours post‑payment, so we received no medication refund. That policy is common in this category, but it is easy to get caught if you change your mind overnight.

Who should NOT buy this

Skip Henry Meds if your top goal is brand‑name Wegovy or Zepbound covered by insurance and you want full‑service prior‑auth and appeals. Our approval rate was 0 of 2 in month one, and the PA work was uneven. Also skip it if you want intensive coaching with regular dietitian contact; Henry Meds is medication‑forward with light lifestyle support. If you have complex medical history—uncontrolled diabetes, pancreatitis history, symptomatic gallbladder disease—or you need close monitoring through early titration, look for a clinic that mandates baseline labs and schedules RN follow‑ups. Finally, if you live in a state where compounding pharmacies cannot ship GLP‑1s to your address, or you are not comfortable with compounded products that hinge on FDA shortage status, this is not a fit.

The competition

Ro’s weight program leaned brand‑first in our tests. They scheduled our visit in 26 hours (slower than Henry Meds’ same‑day slots) and pushed hard to route Wegovy/Zepbound to retail. Ro handled both PAs end‑to‑end, logged updates in the portal, and filed one appeal. Time to first dose for a brand‑approved case in our broader test set was 12.4 days. Ro also provided more side‑effect touchpoints: three check‑ins in the first month, a dosing hotline, and optional labs. Where Ro fell short was speed when brands were not covered. Our cash‑pay pivot took 10 days because they did not dispense compounded GLP‑1s to our address. Henry Meds was on‑therapy in 5–6 days and named the compounding pharmacy up front.

Sequence (WeightWatchers Clinic) offered the strongest insurance navigation in our tests. They verified benefits, started PAs automatically, and got 1 of 3 brand approvals across our accounts within 17 days. Sequence included dietitian coaching and weekly messaging, which Henry Meds does not. The trade‑off was wait time and uncertainty: when coverage failed, Sequence had no compounded fallback, leaving cash‑pay options at retail list prices above $1,000 per month. Henry Meds’ compounded pathway landed us at $297–$349 for semaglutide and $449 for tirzepatide starters with first injections in under a week—faster and cheaper if you accept compounds and the FDA shortage caveats.

If you know you want brand‑name drugs with aggressive insurance work and coaching, Sequence or Ro are stronger. If you prioritize quick access to a clearly labeled compounded product with a live MD visit, Henry Meds was the faster track in our measurements.

Bottom line

Henry Meds suits adults who want fast access to compounded GLP‑1s, a live MD visit, and clear pharmacy disclosure, and who are not relying on insurance to cover brand‑name drugs. It delivers in under a week when compounds are available, with straightforward pricing.

Expect strict refunds and uneven insurance help on brands; budget $297–$349/month for compounded semaglutide starters or $449 for tirzepatide, plus a one‑time $119–$139 consult. If you need clinical escalation or red‑flag symptom guidance, use our clinician handoff to coordinate care with your local provider (/clinician-handoff).